new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12016015746906/09/16 Non-human animals having a humanized cluster of differentiation 274 gene
22016015747006/09/16 Non-human animals having a humanized cluster of differentiation 47 gene
32016015076706/02/16 Mirna-regulated differentiation-dependent self-deleting cassette
42016015271706/02/16 Methods for treating dry eye disease by administering an il-6r antagonist
52016015271806/02/16 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
62016014402505/26/16 Methods and formulations for treating vascular eye diseases
72016014402905/26/16 Anti-erbb3 antibodies and uses thereof
82016014564605/26/16 Methods and compositions for targeted genetic modification using paired guide rnas
92016013774505/19/16 Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
102016013774605/19/16 Methods for treating high cardiovascular risk patients with hypercholesterolemia
112016013032005/12/16 Modified chimeric polypeptides with improved pharmacokinetic properties
122016012094105/05/16 Methods of using il-1 antagonists to treat alzheimer's disease
132016012243305/05/16 Anti-pdgfr-beta antibodies and uses thereof
142016011524604/28/16 Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
152016011548604/28/16 Nuclease-mediated dna assembly
162016011550204/28/16 Novel cho integration sites and uses thereof
172016010836004/21/16 Genetic modification of rats
182016010836904/21/16 Methods and compositions for generating or maintaining pluripotent cells
192016010056104/14/16 Non-human animals with modified immunoglobulin heavy chain sequences
202016010115204/14/16 Use of a vegf antagonist to treat angiogenic eye disorders
212016010118104/14/16 Process for reducing subvisible particles in a pharmaceutical formulation
222016010214704/14/16 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
232016009705904/07/16 Enhanced expression and stability regions
242016009041003/31/16 Fucosylation-deficient cells
252016008131403/24/16 Chimeric antigen receptors
262016008346603/24/16 Anti-il-25 antibodies and uses thereof
272016007577203/17/16 Treatment of fibrodysplasia ossificans progressiva
282016007577803/17/16 Anti-glucagon antibodies and uses thereof
292016005797903/03/16 Human lambda light chain mice
302016006035903/03/16 Human lambda light chain mice
312016006065703/03/16 Methods and compositions for the targeted modification of a genome
322016005089602/25/16 Non-human animals having a humanized signal-regulatory protein gene
332016005298602/25/16 Humanized il-7 rodents
342016005328002/25/16 Efficient selectivity of recombinant proteins
352016004556602/18/16 Angiopoietin-based interventions for treating cerebral malaria
362016004696002/18/16 Methods and compositions for targeted genetic modifications and methods of use
372016003059102/04/16 Biologically active molecules, conjugates thereof, and therapeutic uses
382016003201502/04/16 Stabilized formulations containing anti-pcsk9 antibodies
392016003353002/04/16 Isolating cells expressing secreted proteins
402016002185601/28/16 Genetically modified t cell receptor mice
412016002414701/28/16 Purification platform for bispecific antibodies
422016002419501/28/16 Human antibodies to grem1
432016002420801/28/16 Human antibodies to nav1.7
442016001702901/21/16 Stabilized formulations containing anti-ngf antibodies
452016000757901/14/16 Humanized dipeptidyl peptidase iv (dpp4) animals
462016000233201/07/16 Anti-asic1 antibodies and uses thereof
472016000234101/07/16 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
482015037626712/31/15 Human antibodies to human delta like ligand 4
492015037626912/31/15 Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
502015037662812/31/15 Nuclease-mediated dna assembly
512015037665012/31/15 Methods and compositions for modifying a targeted locus
522015037665112/31/15 Methods and compositions for targeted genetic modifications and methods of use
532015036617412/24/15 Non-human animals having a humanized programmed cell death 1 gene
542015036617512/24/15 Humanized il-15 animals
552015035137112/10/15 Hybrid light chain mice
562015035137212/10/15 Humanized dipeptidyl peptidase iv (dpp4) animals
572015035363412/10/15 Production cell line enhancers
582015034216312/03/15 Genetically modified major histocompatibility complex mice
592015033702911/26/15 Human antibodies to middle east respiratory syndrome - coronavirus spike protein
602015033704311/26/15 Anti-egfr antibodies and uses thereof
612015033704511/26/15 Human antibodies to the glucagon receptor
622015032752411/19/15 Genetically modified non-human animals expressing human epo
632015033099811/19/15 Vegf-a121 assay
642015033099911/19/15 Vegf-a121 assay
652015032002111/12/15 Humanized il-4 and il-4ra animals
662015032002211/12/15 Humanized il-4 and il-4ra animals
672015032002311/12/15 Human lambda light chain mice
682015031319311/05/15 Common light chain mouse
692015031319411/05/15 Humanized c5 and c3 animals
702015031319511/05/15 Low affinity fcgr deficient mice
712015029930310/22/15 Human antibodies to fel d1 and methods of use thereof
722015029930910/22/15 Production cell line enhancers
732015029931010/22/15 Production cell line enhancers
742015028948910/15/15 Non-human animals that make single domain binding proteins
752015029197810/15/15 Mirna-regulated differentiation-dependent self-deleting cassette
762015028246310/08/15 Non-human animals having humanized fc-gamma receptors
772015028447410/08/15 Anti-pcsk9 antibodies with ph-dependent binding characteristics
782015027209210/01/15 Humanized il-6 and il-6 receptor
792015026695709/24/15 Anti-prokineticin receptor (prokr) antibodies and uses thereof
802015026696609/24/15 Methods and antibody compositions for tumor treatment
812015026697609/24/15 Vl antigen binding proteins exhibiting distinct binding characteristics
822015025942309/17/15 Anti-egfrviii antibodies and uses thereof
832015025015109/10/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
842015025210709/10/15 Aplnr modulators and uses thereof
852015024559809/03/15 Genetically modified major histocompatibility complex animals
862015024611909/03/15 Methods for treating or preventing asthma by administering an il-4r antagonist
872015024697309/03/15 Methods for treating skin infection by administering an il-4r antagonist
882015024697609/03/15 Hybrid light chain mice
892015024697709/03/15 Hybrid light chain mice
902015023123608/20/15 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
912015023254508/20/15 Human antibodies to human delta like ligand 4
922015020862207/30/15 Genetically modified non-human animals and methods of use thereof
932015021077607/30/15 Adam6 mice
942015020158907/23/15 Adam6 mice
952015020357907/23/15 Human antibodies to pd-1
962015020358007/23/15 Human antibodies to pd-l1
972015020359107/23/15 Mutivalent antigen-binding proteins
982015019601507/16/15 Mice that make heavy chain antibodies
992015019755307/16/15 Mice that make heavy chain antibodies
1002015019755407/16/15 Mice that make heavy chain antibodies
1012015019755507/16/15 Mice that make heavy chain antibodies
1022015019755607/16/15 Mice that make heavy chain antibodies
1032015019755707/16/15 Mice that make heavy chain antibodies
1042015019756407/16/15 Anti-angptl3 antibodies and uses thereof
1052015019757807/16/15 Anti-tie2 antibodies and uses thereof
1062015019153407/09/15 Human antibodies to human delta like ligand 4
1072015017333106/25/15 Human lambda light chain mice
1082015017333206/25/15 Human lambda light chain mice
1092015017567606/25/15 Fusion polypeptides capable of activating receptors
1102015017568806/25/15 Production cell line enhancers
1112015017600206/25/15 Human lambda light chain mice
1122015016559806/18/15 Devices and methods for facilitating treatment of electrospray columns
1132015016664706/18/15 Antikine antibodies that bind to multiple cc chemokines
1142015016021506/11/15 Isolating cells expressing secreted proteins
1152015015217706/04/15 High affinity human antibodies to human angiopoietin-2
1162015015219106/04/15 Dosing regimens for use with pcsk9 inhibitors
1172015014734205/28/15 Methods for treating cancer by administering an anti-ang-2 antibody
1182015014000205/21/15 Use of a pcsk9 inhibitor to treat hyperlipidemia
1192015014355805/21/15 Non-human animals having a humanized b-cell activating factor gene
1202015014355905/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1212015014356105/21/15 Non-human animals having a humanized b-cell activating factor gene
1222015014356205/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1232015011955604/30/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1242015011075404/23/15 High resolution allele identification
1252015011080104/23/15 Human antibodies to gfr alpha 3 and methods of use thereof
1262015010573504/16/15 Syringe pistons, systems and methods
1272015010696104/16/15 Humanized il-15 animals
1282015009929604/09/15 Promoter-regulated differentiation-dependent self-deleting cassette
1292015010003004/09/15 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1302015008967803/26/15 Non-human animals having a humanized signal-regulatory protein gene
1312015008967903/26/15 Non-human animals having a humanized signal-regulatory protein gene
1322015008968003/26/15 Human lambda light chain mice
1332015007908703/19/15 Vegf antagonist formulations
1342015008246903/19/15 Humanized il-7 rodents
1352015006418903/05/15 Method of treating cancer with dll4 antagonist and chemotherapeutic agent
1362015006790103/05/15 Production of fertile xy female animals from xy es cells
1372015005622102/26/15 Anti-prlr antibodies and uses thereof
1382015005622202/26/15 Anti-prlr antibodies and uses thereof
1392015005900902/26/15 Methods for making fully human bispecific antibodies using a common light chain
1402015004706102/12/15 Humanized m-csf mice
1412015004706202/12/15 Lincrna-deficient non-human animals
1422015003733902/05/15 Anti-activin a antibodies and uses thereof
1432015004025302/05/15 Genetically modified major histocompatibility complex mice
1442015002441201/22/15 Humanized fcgammar mice
1452015001717601/15/15 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
1462015001718201/15/15 Methods for treating nasal polyposis by administering an il-4r antagonist
1472015002022401/15/15 Non-human animals with modified immunoglobulin heavy chain sequences
1482015001056801/08/15 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1492015001302201/08/15 Humanized il-6 and il-6 receptor
1502015001302301/08/15 Humanized il-6 and il-6 receptor
1512014035637012/04/14 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
1522014035637112/04/14 Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1532014035637212/04/14 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
1542014033134011/06/14 Methods and compositions for generating a mouse
1552014032221510/30/14 Methods of inhibiting tumor growth by antagonizing il-6 receptor
1562014031524910/23/14 Inducible eukaryotic expression system
1572014028987609/25/14 Mice that make heavy chain antibodies
1582014027164209/18/14 Il-33 antagonists and uses thereof
1592014027165309/18/14 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
1602014027165809/18/14 Anti-il-33 antibodies and uses thereof
1612014027168109/18/14 High affinity human antibodies to human il-4 receptor
1622014027309509/18/14 Serum-free cell culture medium
1632014027548909/18/14 Apelin fusion proteins and uses thereof
1642014028315809/18/14 Rodents with conditional acvr1 mutant alleles
1652014025539009/11/14 Method of treating rheumatoid arthritis with an anti-il-6r antibody
1662014025541909/11/14 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1672014025542909/11/14 Methods of treating autoimmune diseases with dll4 antagonists
1682014025599509/11/14 High affinity antibodies to human il-6 receptor
1692014024866409/04/14 Readily isolated bispecific antibodies with native immunoglobulin format
1702014024350408/28/14 Antibodies comprising chimeric constant domains
1712014024546608/28/14 Humanized t cell co-receptor mice
1722014024546708/28/14 Genetically modified major histocompatibility complex mice
1732014024546808/28/14 Non-human animals with modified immunoglobulin heavy chain sequences
1742014022002308/07/14 Method of treating osteoarthritis with an antibody to ngf
1752014021377307/31/14 Adam6 mice
1762014019655007/17/14 Systems and devices for sample handling
1772014019976107/17/14 Promoter-regulated differentiation-dependent self-deleting cassette
1782014019340207/10/14 Anti-pdgfr-beta antibodies and uses thereof
1792014019459707/10/14 Modified chimeric polypeptides with improved pharmacokinetic properties
1802014018990007/03/14 Mirna-regulated differentiation-dependent self-deleting cassette
1812014017887906/26/14 Compositions and methods for modifying cells
1822014017990306/26/14 High affinity human antibodies to human protease-activated receptor 2
1832014015470106/05/14 Humanized fc gamma r mice
1842014015568906/05/14 Methods of modifying genes in eukaryotic cells
1852014015744506/05/14 Low affinity fcgr deficient mice
1862014013797805/22/14 System and methods for use in dispensing biopharmaceutical materials
1872014013416905/15/14 Methods of treating ovarian cancer with dll4 antagonists
1882014013418905/15/14 Anti-prokineticin receptor (prokr) antibodies and uses thereof
1892014013471905/15/14 Recombinant cell surface capture proteins
1902014013727505/15/14 Hybrid light chain mice
1912014013019305/08/14 Mice that make vl binding proteins
1922014013019405/08/14 Mice that make vl binding proteins
1932014012010905/01/14 Human antibodies to human tnf-like ligand 1a (tl1a)
1942014011293004/24/14 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1952014009931204/10/14 Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
1962014008829503/27/14 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
1972014008276003/20/14 Non-human animals expressing ph-sensitive immunoglobulin sequences
1982014007256303/13/14 Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
1992014007258303/13/14 Methods for treating atopic dermatitis by administering an il-4r antagonist
2002014007297903/13/14 Isolating cells expressing secreted proteins
2012014007298003/13/14 Isolating cells expressing secreted proteins
2022014007301003/13/14 Methods of modifying eukaryotic cells
2032014007558603/13/14 Parental cell lines for making cassette-free f1 progeny
2042014005690302/27/14 Human antibodies to gfr alpha 3 and methods of use thereof
2052014005690702/27/14 Anti-asic1 antibodies and uses thereof
2062014004473002/13/14 Anti-pcsk9 antibodies with ph-dependent binding characteristics
2072014004106802/06/14 Methods of modifying eukaryotic cells
2082014003333601/30/14 Methods of modifying eukaryotic cells
2092014003333701/30/14 Methods of modifying eukaryotic cells
2102014002363701/23/14 Methods of modifying eukaryotic cells
2112014001722801/16/14 Humanized light chain mice
2122014001722901/16/14 Methods of modifying eukaryotic cells
2132014001723801/16/14 Methods of modifying eukaryotic cells
2142014001769501/16/14 Isolating cells expressing secreted proteins
2152014001778101/16/14 Methods of modifying eukaryotic cells
2162014001778201/16/14 Methods for modifying eukaryotic cells
2172014001852201/16/14 Methods of modifying eukaryotic cells
2182014002012401/16/14 Methods of modifying eukaryotic cells
2192014002012501/16/14 Methods of modifying eukaryotic cells
2202014001345601/09/14 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2212014001345701/09/14 Methods of modifying eukaryotic cells
2222013034453812/26/13 Human antibodies to the glucagon receptor
2232013034010412/19/13 Humanized il-7 rodents
2242013033305712/12/13 Humanized non-human animals with restricted immunoglobulin heavy chain loci
2252013032326012/05/13 Stabilized formulations containing anti-dll4 antibodies
2262013032326112/05/13 Purified antibody composition
2272013032378812/05/13 Production cell line enhancers
2282013032379012/05/13 Human lambda light chain mice
2292013032379112/05/13 Restricted immunoglobulin heavy chain mice
2302013032664712/05/13 Human lambda light chain mice
2312013030967011/21/13 Nuclease-mediated targeting with large targeting vectors
2322013031212811/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2332013031212911/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2342013029509711/07/13 Human antibodies to fel d1 and methods of use thereof
2352013028075810/24/13 Fusion polypeptides capable of activating receptors
2362013027307010/17/13 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
2372013026657410/10/13 Human antibodies to human angiopoietin-like protein 4
2382013025987610/03/13 Anti-hla-b*27 antibodies and uses thereof
2392013025988110/03/13 Fusion polypeptides capable of activating receptors
2402013026105610/03/13 Vegf antagonist formulations
2412013025172809/26/13 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
2422013025491109/26/13 Adam6 mice
2432013024377509/19/13 Multispecific antigen-binding molecules and uses thereof
2442013024378409/19/13 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
2452013024723409/19/13 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2462013024723509/19/13 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
2472013024723609/19/13 Non-human animals expressing ph-sensitive immunoglobulin sequences
2482013023053109/05/13 Human antibodies to clostridium difficile toxins
2492013023053309/05/13 Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###